Pamplona

• A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors Ended
  2023-508280-69-00 1 2022-10-07 Advanced Malignant Tumors
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic M … Ended
  2023-507208-30-00 10 2022-09-20 Diabetic Macular Edema (DME)
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo … Ended
  2024-511750-53-00 7 2022-09-08 Unresectable Locally Advanced or Metastatic Cancer
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 9 2022-09-02 Advanced/metastatic hepatocellular carcinoma (HCC)
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination … Ended
  2024-511744-27-00 1 2022-06-27 Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial
• A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re … Ended
  2023-507140-37-00 4 2022-06-22 Adult patients with relapsed and refractory multiple myeloma
• RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended
  2023-505441-69-00 5 2022-05-17 refractory, advanced gastro-oesophageal cancer
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• Open-label extesnion study of soticlestat in Dravet and Lennox-Gastaut Syndromes Ended
  2022-502802-34-00 5 2022-04-05 Dravet and Lennox-Gastaut Syndromes
• "OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T … Ended
  2023-505097-16-00 4 2022-04-04 Ovarian Neoplasms
• A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma. Ended
  2023-505079-65-00 1 2022-04-01 Multiple myeloma
• ​​Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300)​ Ended
  2024-511187-81-00 5 2022-03-28 Colorectal Cancer (CRC)
• A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma … Ended
  2023-509917-35-00 4 2022-03-21 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (
• A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Pa … Ended
  2023-506310-43-00 1 2022-02-15 BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation
• EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib … Ended
  2024-513023-17-00 5 2022-01-12 Treatment of acute graft-versus host disease (aGvHD) to the gastrointe
• A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended
  2024-512052-38-00 9 2021-12-02 Advanced triple negative breast cancer
• A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Ended
  2024-511999-32-00 9 2021-11-19 Advanced/Metastatic EGFR-expressing Cancers
• A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER) Ended
  2024-516824-32-00 5 2021-11-15 Covid19 Corona Virus Infection
• Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended
  2023-510511-19-00 7 2021-11-08 Advanced Solid Tumors

Showing 721–744 of 821 trials